Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Clinical trial NCT00466531 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT00466531
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-03-21
- Primary completion
- 2026-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.